Litcius/Paper detail

Anti-Ro52 antibody is highly prevalent and a marker of better prognosis in patients with ovarian cancer

Dimitrios P. Bogdanos, Athanasios Gkoutzourelas, Vasileios Papadopoulos, Christos Liaskos, Eleni Patrikiou, Christina Tsigalou, Athanasios Saratziotis, Jiannis Hajiioannou, Thomas Scheper, Wolfgang Meyer, Lazaros I. Sakkas, Christos N. Papandreou

2021Clinica Chimica Acta21 citationsDOI

Topics & Concepts

Ovarian cancerEpitopeMedicineAntibodyImmunoassayImmunologyClinical significanceOncologyCancerInternal medicineSystemic Lupus Erythematosus ResearchT-cell and B-cell ImmunologyMonoclonal and Polyclonal Antibodies Research
Anti-Ro52 antibody is highly prevalent and a marker of better prognosis in patients with ovarian cancer | Litcius